We also demonstrated that combination therapy with a HER2 inhibitor and a AKT inhibitor, as well as other PI3K/AKT/mTOR pathway inhibitors, could overcome the therapeutic limitations associated with anti-HER2 monotherapy in the PIK3CA-mutant HER2+ breast cancers. Here, ERBB2 is linked to breast carcinoma.